<p>瑞穗证券美国有限公司在其最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第一季度将其在美敦力公司（NYSE:MDT - 免费报告）的股份减少了 15.5%。该机构投资者在此期间出售了 18,877 股后，持有 102,672 股该医疗技术公司的股票。瑞穗证券美国有限公司在美敦力的持股在最近的报告期末价值为 9,226,000 美元。</p>
<ul>
<li>未来自动化的 5 只机器人股票</li>
</ul>
<p>其他几家机构投资者也对该公司的股份进行了增减。布莱顿琼斯有限公司在第四季度将其在美敦力的持股增加了 1,368.0%。布莱顿琼斯有限公司目前持有 39,989 股该医疗技术公司的股票，价值为 3,194,000 美元，此前在上个季度又购买了 37,265 股。FMR 有限公司在第四季度将其在美敦力的持股增加了 14.4%。FMR 有限公司目前持有 2,104,985 股该医疗技术公司的股票，价值为 168,146,000 美元，此前在上个季度又购买了 265,416 股。FIL 有限公司在第四季度将其在美敦力的持股增加了 16.0%。FIL 有限公司目前持有 5,414 股该医疗技术公司的股票，价值为 432,000 美元，此前在上个季度又购买了 748 股。CenterBook Partners LP 在第四季度将其在美敦力的持股增加了 86.4%。CenterBook Partners LP 目前持有 16,344 股该医疗技术公司的股票，价值为 1,306,000 美元，此前在上个季度又购买了 7,577 股。最后，凤凰金融有限公司在第四季度将其在美敦力的持股增加了 5.8%。凤凰金融有限公司目前持有 5,014 股该医疗技术公司的股票，价值为 403,000 美元，此前在上个季度又购买了 277 股。目前 82.06% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师最近对该股票发布了报告。加拿大皇家银行将美敦力的目标股价从 105.00 美元下调至 101.00 美元，并在 5 月 22 日的报告中对该公司给予了 “跑赢大盘” 的评级。华尔街 Zen 将美敦力的评级从 “买入” 下调至 “持有”。瑞穗在 7 月 16 日的报告中将美敦力的目标股价从 98.00 美元上调至 100.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 4 月 11 日的报告中将美敦力的目标股价从 93.00 美元下调至 90.00 美元，并对该公司给予了 “持有” 的评级。最后，沃尔夫研究在 6 月 30 日的报告中将美敦力的评级从 “表现不佳” 上调至 “同业表现”。共有 12 位分析师对该股票给予了 “持有” 评级，9 位给予了 “买入” 评级，2 位给予了 “强烈买入” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 98.19 美元。</p>
<ul>
<li>3 只安全的买入持有型高股息股票，财务状况良好</li>
</ul>
<p><strong>阅读我们关于美敦力的最新股票报告</strong></p>
<h2>美敦力股票表现</h2>
<p>美敦力的股票在周五开盘价为 92.94 美元。该公司的流动比率为 1.85，速动比率为 1.42，债务与股本比率为 0.53。该股票的市值为 1191.3 亿美元，市盈率为 25.67，市盈增长比率为 2.37，贝塔值为 0.80。该公司的 50 日简单移动平均线为 88.65 美元，200 日简单移动平均线为 87.93 美元。美敦力的 12 个月低点为 79.29 美元，12 个月高点为 96.25 美元。</p>
<ul>
<li>直觉外科：在贸易与领土战争中是利润还是危险？</li>
</ul>
<p>美敦力（NYSE:MDT - 获取免费报告）最近在 5 月 21 日发布了季度财报。该医疗技术公司报告季度每股收益为 1.62 美元，超出分析师一致预期的 1.58 美元，超出 0.04 美元。该业务的季度收入为 89.3 亿美元，而分析师预期为 88.1 亿美元。美敦力的净利润率为 13.90%，股本回报率为 14.54%。该业务的季度收入较去年同期增长了 3.9%。在去年同期，该公司每股收益为 1.46 美元。分析师预测，美敦力 PLC 在当前年度的每股收益将达到 5.46 美元。</p>
<h2>美敦力增加股息</h2>
<p>该公司最近还披露了季度股息，已于 7 月 11 日支付。6 月 27 日的股东获得每股 0.71 美元的股息。这比美敦力之前的季度股息 0.70 美元有所增加。该股息的除息日期为 6 月 27 日。这相当于年化股息为 2.84 美元，股息收益率为 3.1%。美敦力的派息比率目前为 78.45%。</p>
<h2>美敦力简介</h2>
<p>（免费报告）</p>
<p>美敦力公司开发、制造和销售基于设备的医疗疗法，服务于全球的医疗系统、医生、临床医生和患者。其心血管产品组合提供可植入的心脏起搏器、心脏复律除颤器和心脏再同步治疗设备；心脏消融产品；可植入心脏监测系统；TYRX 产品；以及远程监控和以患者为中心的软件。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票超过美敦力</li>
<li>3 只最佳金融科技股票以提升投资组合</li>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
<li>制造业股票投资</li>
<li>爱彼迎超出收益预期，但增长故事正在失去高度</li>
<li>如何利用分析师评级进行交易</li>
<li>Netflix 的多头与空头：谁将在这次回调中获胜？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在美敦力吗？</h2>
<p>在考虑美敦力之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而美敦力并不在名单上。</p>
<p>虽然美敦力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

瑞穗金融集团

美敦力

<p>瑞穗证券美国有限公司在第一季度将其在美敦力（NYSE:MDT）的持股减少了 15.5%，目前持有 102,672 股，价值 923 万美元。其他机构投资者，包括 Brighton Jones LLC 和 FMR LLC，则增加了他们的持仓。分析师对美敦力的评级各不相同，普遍评级为 “适度买入”，目标价为 98.19 美元。美敦力的股票开盘价为 92.94 美元，市值为 1191.3 亿美元，最近的每股收益为 1.62 美元，超出预期。该公司还宣布将于 7 月 11 日支付季度股息</p>

<p>Mizuho Securities USA LLC reduced its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 15.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,672 shares of the medical technology company's stock after selling 18,877 shares during the period. Mizuho Securities USA LLC's holdings in Medtronic were worth $9,226,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>瑞穗证券美国有限公司在其最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第一季度将其在美敦力公司（NYSE:MDT - 免费报告）的股份减少了 15.5%。该机构投资者在此期间出售了 18,877 股后，持有 102,672 股该医疗技术公司的股票。瑞穗证券美国有限公司在美敦力的持股在最近的报告期末价值为 9,226,000 美元。</p>
</div><ul>
<li>5 Robotics Stocks to Buy for the Future of Automation</li>
</ul>
<div class="lb-trans"><ul>
<li>未来自动化的 5 只机器人股票</li>
</ul>
</div><p>Several other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in shares of Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. FMR LLC increased its holdings in shares of Medtronic by 14.4% during the fourth quarter. FMR LLC now owns 2,104,985 shares of the medical technology company's stock worth $168,146,000 after buying an additional 265,416 shares in the last quarter. FIL Ltd increased its holdings in shares of Medtronic by 16.0% during the fourth quarter. FIL Ltd now owns 5,414 shares of the medical technology company's stock worth $432,000 after buying an additional 748 shares in the last quarter. CenterBook Partners LP increased its holdings in shares of Medtronic by 86.4% during the fourth quarter. CenterBook Partners LP now owns 16,344 shares of the medical technology company's stock worth $1,306,000 after buying an additional 7,577 shares in the last quarter. Finally, Phoenix Financial Ltd. increased its holdings in shares of Medtronic by 5.8% during the fourth quarter. Phoenix Financial Ltd. now owns 5,014 shares of the medical technology company's stock worth $403,000 after buying an additional 277 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者也对该公司的股份进行了增减。布莱顿琼斯有限公司在第四季度将其在美敦力的持股增加了 1,368.0%。布莱顿琼斯有限公司目前持有 39,989 股该医疗技术公司的股票，价值为 3,194,000 美元，此前在上个季度又购买了 37,265 股。FMR 有限公司在第四季度将其在美敦力的持股增加了 14.4%。FMR 有限公司目前持有 2,104,985 股该医疗技术公司的股票，价值为 168,146,000 美元，此前在上个季度又购买了 265,416 股。FIL 有限公司在第四季度将其在美敦力的持股增加了 16.0%。FIL 有限公司目前持有 5,414 股该医疗技术公司的股票，价值为 432,000 美元，此前在上个季度又购买了 748 股。CenterBook Partners LP 在第四季度将其在美敦力的持股增加了 86.4%。CenterBook Partners LP 目前持有 16,344 股该医疗技术公司的股票，价值为 1,306,000 美元，此前在上个季度又购买了 7,577 股。最后，凤凰金融有限公司在第四季度将其在美敦力的持股增加了 5.8%。凤凰金融有限公司目前持有 5,014 股该医疗技术公司的股票，价值为 403,000 美元，此前在上个季度又购买了 277 股。目前 82.06% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have recently issued reports on the stock. Royal Bank Of Canada lowered their price target on shares of Medtronic from $105.00 to $101.00 and set an &#34;outperform&#34; rating for the company in a report on Thursday, May 22nd. Wall Street Zen downgraded Medtronic from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday. Mizuho increased their price objective on Medtronic from $98.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, July 16th. Truist Financial decreased their price objective on Medtronic from $93.00 to $90.00 and set a &#34;hold&#34; rating for the company in a report on Friday, April 11th. Finally, Wolfe Research upgraded Medtronic from an &#34;underperform&#34; rating to a &#34;peer perform&#34; rating in a report on Monday, June 30th. Twelve analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $98.19.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票发布了报告。加拿大皇家银行将美敦力的目标股价从 105.00 美元下调至 101.00 美元，并在 5 月 22 日的报告中对该公司给予了 “跑赢大盘” 的评级。华尔街 Zen 将美敦力的评级从 “买入” 下调至 “持有”。瑞穗在 7 月 16 日的报告中将美敦力的目标股价从 98.00 美元上调至 100.00 美元，并给予该公司 “跑赢大盘” 的评级。Truist Financial 在 4 月 11 日的报告中将美敦力的目标股价从 93.00 美元下调至 90.00 美元，并对该公司给予了 “持有” 的评级。最后，沃尔夫研究在 6 月 30 日的报告中将美敦力的评级从 “表现不佳” 上调至 “同业表现”。共有 12 位分析师对该股票给予了 “持有” 评级，9 位给予了 “买入” 评级，2 位给予了 “强烈买入” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 98.19 美元。</p>
</div><ul>
<li>3 Safe Buy-and-Hold Dividend Stocks With Strong Balance Sheets</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只安全的买入持有型高股息股票，财务状况良好</li>
</ul>
</div><p><strong>Read Our Latest Stock Report on Medtronic</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于美敦力的最新股票报告</strong></p>
</div><h2>Medtronic Stock Performance</h2>
<div class="lb-trans"><h2>美敦力股票表现</h2>
</div><p>Shares of MDT opened at $92.94 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.42 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $119.13 billion, a P/E ratio of 25.67, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80. The firm's fifty day simple moving average is $88.65 and its two-hundred day simple moving average is $87.93. Medtronic PLC has a 12 month low of $79.29 and a 12 month high of $96.25.</p>
<div class="lb-trans"><p>美敦力的股票在周五开盘价为 92.94 美元。该公司的流动比率为 1.85，速动比率为 1.42，债务与股本比率为 0.53。该股票的市值为 1191.3 亿美元，市盈率为 25.67，市盈增长比率为 2.37，贝塔值为 0.80。该公司的 50 日简单移动平均线为 88.65 美元，200 日简单移动平均线为 87.93 美元。美敦力的 12 个月低点为 79.29 美元，12 个月高点为 96.25 美元。</p>
</div><ul>
<li>Intuitive Surgical: Profit or Peril Ahead Amid Trade &amp; Turf Wars?</li>
</ul>
<div class="lb-trans"><ul>
<li>直觉外科：在贸易与领土战争中是利润还是危险？</li>
</ul>
</div><p>Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 21st. The medical technology company reported $1.62 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.04. The business had revenue of $8.93 billion for the quarter, compared to analysts' expectations of $8.81 billion. Medtronic had a net margin of 13.90% and a return on equity of 14.54%. The business's quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.46 earnings per share. As a group, analysts predict that Medtronic PLC will post 5.46 EPS for the current year.</p>
<div class="lb-trans"><p>美敦力（NYSE:MDT - 获取免费报告）最近在 5 月 21 日发布了季度财报。该医疗技术公司报告季度每股收益为 1.62 美元，超出分析师一致预期的 1.58 美元，超出 0.04 美元。该业务的季度收入为 89.3 亿美元，而分析师预期为 88.1 亿美元。美敦力的净利润率为 13.90%，股本回报率为 14.54%。该业务的季度收入较去年同期增长了 3.9%。在去年同期，该公司每股收益为 1.46 美元。分析师预测，美敦力 PLC 在当前年度的每股收益将达到 5.46 美元。</p>
</div><h2>Medtronic Increases Dividend</h2>
<div class="lb-trans"><h2>美敦力增加股息</h2>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Friday, July 11th. Stockholders of record on Friday, June 27th were given a dividend of $0.71 per share. This is a boost from Medtronic's previous quarterly dividend of $0.70. The ex-dividend date of this dividend was Friday, June 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic's payout ratio is currently 78.45%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，已于 7 月 11 日支付。6 月 27 日的股东获得每股 0.71 美元的股息。这比美敦力之前的季度股息 0.70 美元有所增加。该股息的除息日期为 6 月 27 日。这相当于年化股息为 2.84 美元，股息收益率为 3.1%。美敦力的派息比率目前为 78.45%。</p>
</div><h2>Medtronic Profile</h2>
<div class="lb-trans"><h2>美敦力简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.</p>
<div class="lb-trans"><p>美敦力公司开发、制造和销售基于设备的医疗疗法，服务于全球的医疗系统、医生、临床医生和患者。其心血管产品组合提供可植入的心脏起搏器、心脏复律除颤器和心脏再同步治疗设备；心脏消融产品；可植入心脏监测系统；TYRX 产品；以及远程监控和以患者为中心的软件。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Medtronic</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>MarketBeat Week in Review – 08/04 - 08/08</li>
<li>Manufacturing Stocks Investing</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>How to trade using analyst ratings</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过美敦力</li>
<li>3 只最佳金融科技股票以提升投资组合</li>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
<li>制造业股票投资</li>
<li>爱彼迎超出收益预期，但增长故事正在失去高度</li>
<li>如何利用分析师评级进行交易</li>
<li>Netflix 的多头与空头：谁将在这次回调中获胜？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=MDT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Medtronic Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在美敦力吗？</h2>
</div><p>Before you consider Medtronic, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑美敦力之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而美敦力并不在名单上。</p>
</div><p>While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然美敦力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

瑞穗证券美国有限责任公司持有美敦力公司（纽约证券交易所代码：MDT）价值 923 万美元的股票头寸